Kaye Edward M. MD has demonstrated a clear selling bias in recent insider transactions, with $7.57 million in total sales compared to just $487,446 in buys across 46 reported trades. The activity is concentrated in three biotech stocks: STOK, RNAM, and CYTK. Notably, all 13 of Kaye’s most recent transactions since December 2025 have been sales or dispositions, with no purchases recorded. The largest single sale occurred on December 1, 2025, when Kaye disposed of Cytokinetics (CYTK) shares worth $1.87 million. Shortly after, between December 2–8, 2025, Kaye executed a series of sales in Stoke Therapeutics (STOK) totaling over $700,000, including a single $269,070 transaction on December 8.
The pattern shifted slightly in early 2026, with Kaye reporting multiple dispositions of RNAM shares on February 27 and STOK transactions on March 15, though these later filings listed no dollar values. The only non-sale in recent months was a January 15, 2026 acquisition of CYTK shares worth $12,498, which stands in stark contrast to the earlier $1.87 million sale of the same stock. With no buys in STOK or RNAM and consistent selling across all three holdings, Kaye’s activity suggests a net reduction in exposure to these positions, particularly in CYTK and STOK where the dollar volumes were highest. The absence of material purchases since early 2026 reinforces this directional trend.
AI-assisted summary